Go Pro
NASDAQ:MSLE

Satellos Bioscience Q1 2026 Earnings Report

$10.01 -0.02 (-0.20%)
As of 08/10/2026 04:00 PM Eastern

Satellos Bioscience EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Satellos Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Satellos Bioscience Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Satellos Bioscience Earnings Headlines

Satellos Bioscience Inc
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Satellos Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email.

About Satellos Bioscience

Satellos Bioscience (NASDAQ:MSLE) is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.

View Satellos Bioscience Profile